Clinical Trials Logo

Clinical Trial Summary

This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of California, San Francisco (UCSF).


Clinical Trial Description

PRIMARY OBJECTIVES: I. To demonstrate the tolerability of nisin administration, as assessed by the maximum tolerated dose (MTD) of nisin (Phase I). II. To demonstrate the feasibility of nisin administration, as assessed by the treatment completion rate (Phase IIa). SECONDARY OBJECTIVES: I. To evaluate the safety of nisin administration, as assessed by the frequency and severity of adverse events (CTCAE v5.0) (Phase I). II. To evaluate externally measured changes in primary and nodal tumor size on intraoral examination from baseline to time of surgery, as assessed by cross-sectional measurement of tumors/ulceration with calipers during dental exam (Phase IIa). III. To evaluate clinical changes in periodontal condition on dental examination over the study period, as assessed according to the American Academy of Periodontology grading system (Phase IIa). EXPLORATORY OBJECTIVES: I. To characterize nisin-induced changes in oral microbiome population structure and function, and nisin sensitivity among key oral bacterial species. II. To characterize inflammatory and anti-tumor cellular responses to nisin in the oral cancer environment. III. To confirm the half-life and urinary excretion profile of nisin (Phase 1). IV. To demonstrate the preliminary efficacy of nisin administration, as assessed by relapse-free survival (RFS) and overall survival (OS) (Phase IIa). OUTLINE: Participants receiving treatment at UCSF will be initially assigned to the Phase 1 dose finding arm. After an interim analysis is completed, enrollment into Phase IIa will begin at the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Participants will be treated for two weeks before planned surgery, complete OSCC resection surgery (standard of care, non-interventional) and will continue treatment for 6 additional months post-surgery. Follow-up will continue for 12 months after surgery. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06097468
Study type Interventional
Source University of California, San Francisco
Contact Angelica Valadez
Phone 415-502-1879
Email Angelica.Valadez@ucsf.edu
Status Recruiting
Phase Phase 1/Phase 2
Start date February 2, 2024
Completion date September 1, 2027

See also
  Status Clinical Trial Phase
Completed NCT03650699 - Biofeedback Rehabilitation to Improve Speaking and Eating in Public N/A
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Terminated NCT03053960 - Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
Recruiting NCT05876247 - Articulatory Adaptation Following Oral Cancer Treatment
Completed NCT03618654 - Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Early Phase 1
Recruiting NCT04801472 - Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) N/A
Recruiting NCT04858269 - First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Phase 2
Active, not recruiting NCT03529604 - Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
Completed NCT03028766 - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer Phase 1
Recruiting NCT05681039 - Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). Phase 2
Completed NCT03510390 - Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation N/A
Recruiting NCT05578170 - Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma
Recruiting NCT05950737 - Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience N/A
Recruiting NCT04333537 - Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer Phase 2/Phase 3
Recruiting NCT03727594 - Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
Terminated NCT02582008 - Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Early Phase 1
Recruiting NCT05749042 - A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma Phase 2
Withdrawn NCT04892875 - A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Phase 1
Active, not recruiting NCT03784066 - Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity Phase 1/Phase 2
Active, not recruiting NCT03381183 - IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma Phase 1